* GSK: The U.S. FDA approved GSK Plc's drug as the first oral treatment for anemia caused by chronic kidney disease in adults.
* CAPRICORN ENERGY: Capricorn Energy shareholders voted in favour of six new directors proposed by activist shareholder Palliser.
* SHELL: Shell has been accused of misleading investors over its renewable energy spending plans in a complaint filed with the U.S. securities regulator by activist group Global Witness.
* UK PHARMA: UK's pharmaceutical trade body called for the government to scrap its plans to raise the repayment rates for drugmakers.
* BOE: The Bank of England is poised to raise interest rates for the 10th time in a row to keep up its fight against rampant inflation, but it might also drop a hint about when the steep climb in borrowing costs will end
* GOLD: Gold prices extended gains on Thursday to touch their highest in more than nine months after the Federal Reserve raised interest rates.
* OIL: Oil prices rebounded on Thursday after tumbling in the previous session as a weaker dollar brought back some appetite for risk assets. The UK's FTSE 100 fell on Wednesday ahead of an interest rate decision from the U.S. Federal Reserve, while investors also grappled with concerns around a slowing British economy and mixed corporate updates. UK CORPORATE DIARY:
Shell Q4 Results
Renishaw HY Resuts
Airtel 9M/ Q3 Results
Africa BT Q3 Trading
update
Cranswick Q3 Trading
update
Anglo Q4 Production
American report
Plc
* For more on the factors affecting European stocks, please click on: TODAY'S UK PAPERS > Financial Times > Other business headlines (Reporting by Sruthi Narasimha Chari in Bengaluru)
